Want to take quizzes and track your credits?
The effectiveness of COVID-19 vaccination remains unknown in patients with hematologic malignant disease who have an impaired humoral immunity from both treatment and disease. Phase 3 registration studies of COVID-19 vaccines excluded patients with immunosuppression or immunosuppressive therapies.1,2 Despite this, professional organizations suggest vaccination, or even its prioritization, for patients with cancer.3 As the US Centers for Disease Control loosens pandemic-related precautions for vaccinated people, a better understanding of the vaccine response among patients with hematologic malignant disease is critical.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
Accepted for Publication: July 12, 2021.
Published Online: August 11, 2021. doi:10.1001/jamaoncol.2021.4381
Corresponding Author: Thomas A. Ollila, MD, Alpert Medical School of Brown University, Rhode Island Hospital, George Bldg, Ste 310, 593 Eddy St, Providence, RI 02903 (firstname.lastname@example.org).
Author Contributions: Dr Ollila had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Ollila, Lu, Rogers, Olszewski.
Acquisition, analysis, or interpretation of data: Ollila, Lu, Masel, Zayac, Paiva, Olszewski.
Drafting of the manuscript: Ollila, Zayac, Paiva, Olszewski.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Olszewski.
Administrative, technical, or material support: Ollila, Lu, Paiva, Rogers, Olszewski.
Supervision: Ollila, Olszewski.
Conflict of Interest Disclosures: Dr Olszewski reported research funding from Genentech, TG Therapeutics, Celldex Pharmaceuticals, and Precision Bio; grants from Acrotech Pharma, Adaptive Biotechnologies outside the submitted work. No other disclosures were reported.
Additional Contributions: In addition to the listed authors, we acknowledge the following individuals for their assistance with this study, none of whom were compensated for his or her contributions and all of whom agree to include their names here: John L. Reagan, MD (Brown Alpert School of Medicine); Peter Barth, MD (Brown Alpert School of Medicine); Rabin Niroula, MD; Gerard J. Nau, MD, PhD (Brown Alpert School of Medicine); Rani Chudasama, MD (Brown Alpert School of Medicine); Inna Yakirevich, NP (Division of Hematology/Oncology, Rhode Island Hospital); and Christopher Elco, MD, PhD (Brown Alpert School of Medicine).
You currently have no searches saved.